News NICE rejects Shire pancreatic cancer drug Onivyde not eligible for Cancer Drugs Fund, says NICE.
News NICE recommends Afinitor, Xalkori, as cancer drug review con... NICE has recommended two cancer drugs, as it continues its review of treatments in the old Cancer Drugs Fund.
News Scotland to fund BMS skin cancer combo Patient evidence convinces SMC Opdivo+Yervoy is cost-effective.
News NICE finally recommends Eisai breast cancer drug after rethi... New trial evidence and price cut convinces NICE in reassessment.
News UK aims to cut four years from drug development process NICE, regulator and NHS should work together, according to review.
UK & Europe NICE says Otezla's bargain price offsets lower efficacy Otezla cheap and convenient, but less effective than rivals, says NICE.
News Kaken details the data behind its PI3K inhibitor filing Kaken has revealed the data that supported its recent marketing application for serabelisib as a treatment for vascular malformations in Japan.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
